<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34362662</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-5411</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>45</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Contact lens &amp; anterior eye : the journal of the British Contact Lens Association</Title>
          <ISOAbbreviation>Cont Lens Anterior Eye</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Improved contact lens fitting after corneal cross-linking in eyes with progressive keratoconus.</ArticleTitle>
        <Pagination>
          <StartPage>101488</StartPage>
          <MedlinePgn>101488</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clae.2021.101488</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1367-0484(21)00117-X</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The study aimed to assess the possible effects of corneal cross-linking (CXL) on contact lens (CL) fitting in patients with progressive keratoconus who initially had CL intolerance.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective review was performed of the medical records of patients who had stopped CL wear due to discomfort prior to CXL and who were fitted with CLs after CXL. All eyes were evaluated pre- and 1, 6, 12, 24 months postoperatively. Data collected included pre- and post-CXL refraction, corneal topographic data, uncorrected visual acuity, and best-corrected visual acuity (BCVA). CL comfort was evaluatedusing theLikert scale post-CXL.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 20 eyes from 14 patients were included in the study. Preoperative Kmax values significantly decreased by 2.8 D at 6 months and by 4.1 D at 12 months after CXL (p &lt; 0.001 for both). CLs were prescribed on average 12 ± 2.5 months after CXL. The mean duration of successful CL wear was 10.4 ± 2.8 months during the follow-up period. Subjective CL comfort scores were satisfactory post-CXL.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CXL not only halts the progression of keratoconus but may also improve CL tolerance by providing a more regular shaped cornea in these patients. Ongoing corneal topographic changes in the late postoperative period after CXL may have a positive effect on CL fitting.</AbstractText>
          <CopyrightInformation>Copyright © 2021. Published by Elsevier Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Isik</LastName>
            <ForeName>Puren</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Nigde Omer Halisdemir University, Faculty of Medicine, Department of Ophthalmology, Nigde, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harbiyeli</LastName>
            <ForeName>Ibrahim Inan</ForeName>
            <Initials>II</Initials>
            <AffiliationInfo>
              <Affiliation>Cukurova University, Faculty of Medicine, Department of Ophthalmology, Adana, Turkey. Electronic address: iharbiyeli@cu.edu.tr.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Erdem</LastName>
            <ForeName>Elif</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Cukurova University, Faculty of Medicine, Department of Ophthalmology, Adana, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yagmur</LastName>
            <ForeName>Meltem</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cukurova University, Faculty of Medicine, Department of Ophthalmology, Adana, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cont Lens Anterior Eye</MedlineTA>
        <NlmUniqueID>9712714</NlmUniqueID>
        <ISSNLinking>1367-0484</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003432">Cross-Linking Reagents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-34-5</RegistryNumber>
          <NameOfSubstance UI="D003094">Collagen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>TLM2976OFR</RegistryNumber>
          <NameOfSubstance UI="D012256">Riboflavin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003094" MajorTopicYN="N">Collagen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003261" MajorTopicYN="Y">Contact Lenses</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003315" MajorTopicYN="N">Cornea</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019781" MajorTopicYN="N">Corneal Topography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003432" MajorTopicYN="N">Cross-Linking Reagents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007640" MajorTopicYN="Y">Keratoconus</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012256" MajorTopicYN="N">Riboflavin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014466" MajorTopicYN="N">Ultraviolet Rays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Contact lens</Keyword>
        <Keyword MajorTopicYN="N">Cross-linking</Keyword>
        <Keyword MajorTopicYN="N">Keratoconus</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>7</Day>
          <Hour>5</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34362662</ArticleId>
        <ArticleId IdType="doi">10.1016/j.clae.2021.101488</ArticleId>
        <ArticleId IdType="pii">S1367-0484(21)00117-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
